Investor Overview

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, and is dedicated to developing innovative, vision-improving treatments for diseases of the retina. Our commitment to retina specialists and their patients is manifest in our product development portfolio being studied to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion.

Alimera Sciences’ advanced product candidate, ILUVIEN, is an intravitreal insert containing fluocinolone acetonide, a corticostercoid which may be useful in the treatment of ocular disease. ILUVIEN is under review at the US FDA and 7 European health authorities for the treatment of DME, a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

Alimera is committed to developing proactive solutions while remaining attuned to market needs and opportunities. Learn more about Alimera with the shareholder tools below.